Faculty of Engineering, LTH

Denna sida på svenska This page in English


Cancer Crosslinks- Registration OPEN

The registration for the 5th Cancer Crosslinks, is now open. This year’s sessions are;

Cancer and the Immune system

Transformative Oncology

Personalized Healthcare – What is next?


with speakers from academia, industry, and health care.

The conference also enables plenty of networking opportunities.

Detailed information on program and registration can be found at:


New test for early discovery of pancreatic cancer.

Immonovia, spin out from CREATE health

The IMMray™ PanCan-d bloodtest, developed to discover pancreatic cancer through a blood test, was mentioned today in the Swedish News Swedish radio (SR) P1, and part of a longer radio broadcast (Vetandets värd), highlighting new discoveries in the field of pancreatic cancer.


The technology platform IMMray™ of Immunovia finds early biomarker signatures for several forms of cancer and autoimmune diseases, which gives it the potential to significantly increase the survival rate and quality of life of many patients. 

Founded on the research of Professor Carl Borrebaeck at Lund University, Immunovia has developed a technology platform, IMMray™(Immunovia Antibody Microarray), for early diagnosis, prognosis and monitoring of cancers and autoimmune diseases. 

”Complex diseases leaves footprints in the immune system. With a simple blood sample we can measure many proteins simultaneously in the immune response and thereby identify clinically relevant biomarker signatures for several forms of cancer, as well as autoimmune diseases like rheumatoid arthritis, Sjögren’s Syndrome, Lupus etc. that are hard to diagnose early,” says Mats Grahn, CEO of the molecular diagnostics company Immunovia.

The company’s first and main product is aimed for early diagnosis of pancreatic cancer. 


For full article please follow the link.

Cancer Crosslinks 25 oktober 2017 SAVE THE DATE


Cancer Crosslinks 2017 will host a range of interesting topics presented by speakers from academia, industry, and health care, as well as plenty of networking opportunities.

Detailed information on program and registration will follow - stay tuned!





The translational Cancer Faster Forward doctoral programme – CanFaster

The EU program 2020 MCSA COFUND has approved a unique doctoral program, CanFaster, focused on translational cancer research. CanFaster, will strengthen the cancer area at Lund university by enabling co-funding of 16 PhD students. In addition to research-specific courses the PhD students will be trained in entrepreneurship as well as get a better understanding of clinical practice and will be offered secondments within industry.

CanFaster build on collaboration between industry, healthcare and academia to strengthen and accelerate innovations and clinical implementation in oncology.

The ultimate goal is to increase patients' chance for a longer and healthier life through rapid implementation of new diagnostic and therapeutic solutions says Prof. Sara Ek, program director.

The program is hosted by CREATE Health and involves three faculties at Lund University. The fourteen researchers behind the application are: Thoas Fioretos, Lao Saal, Kristian Pietras, Lisa Rydén, Signe Borgquist, Kristina Drott, Mef Nilbert, Håkan Axelsson, Peter James, Yvonne Ceder, Sara Ek, Johan Axelsson, Inga-Lill Rahm Hallberg / Per Johansson and Malin Lindstedt.

 "CanFaster is a valuable addition to CREATE Health and we are delighted to be able to further expand collaborations in Oncology at Lund University, nationally and internationally," says Carl Borrebaeck, Director of CREATE Health. 


Fact: The program is run by CREATE Health Translational Cancer Center, and has been granted under the 2020 MCSA COFUND. The program, called “The translational cancer Faster Forward doctoral program – CanFaster”, is a joint venture between industry, healthcare  and academia.


Programme Board

Prof. Carl Borrebaeck – Director of CREATE Health

Prof. Sara Ek – Programme Director

Prof. Kristian Pietras - Director of BioCARE.

Dr. Johanna Asklin - Innovation officer at LU Innovation.

Ms. Ebba Fåhreaus - CEO of SMILE.

Ms. Emma Roybon - Head of Research Administration at the Faculty of Medicine, Lund University.

MD/Prof. Mats Jerkeman - Represenative of Skåne University Hospital.




Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer

Carl Borrebaeck, Director of CREATE Health in Nature Reviews Cancer online magazine.

This Opinion article, written by Professor Carl Borrebaeck, describes the trends and progress being made in identifying protein biomarker signatures of clinical utility in cancer using, in particular, blood-based proteomics. This is one of the research focuses with CREATE Health

CREATE Health satsar på tidig diagnostik och precisionsbehandling

Nyligen publicerades denna artikel om CREATE Health

CREATE Health är ett translationellt cancercentrum vid Lunds Universitet beläget på Medicon Village. Där möts specialister från Universitetsjukhuset och forskare från de vetenskapliga fakulteterna för arbeta mot samma mål, att bota cancer. Två viktiga aspekter för att nå det målet är tidig upptäckt och precisionsbehandling.



Cancer Crosslinks Sweden – Precision Medicine and Immuno-Oncology

Around 200 leading scientists, healthcare providers, pharmaceutical companies and government representatives gathered at the fourth edition of the Cancer Crosslinks Sweden conference. CREATE Health, a strategic centre for translational cancer research at Lund University, hosted the conference and the theme of the day was “Precision Medicine and Immuno-Oncology”.

Read more

Cancer Crosslinks 19 October

Save the date!

Make sure to book the 19 October 2016 in your calendar. Cancer Crosslinks is back in Lund!
Location: Medicon Village, Scheelevägen 2, Lund.

This is the successful conference linking Academia, Health care systems and Industry. Focus: Immunooncology and Perzonalized medicine.


For more information click  here


Pancreatic Cancer Nordic Newsletter includes research from CREATE Health

Based on recent results from retrospective studies, that are now under publication, we can differentiate the early resectable stages of pancreatic cancer, stage I and II, from the healthy controls with 96% accuracy.


Read the article here

CREATE Health research cited in "Cancerfondsrapporten 2016


Vid CREATE Health samlas forskare från laboratorium och klinik för att studera biomarkörer och molekylära signaturer. De är bland annat på god väg att få fram nya tester för bättre diagnostik och behandling av cancer i bröst och bukspottkörtel.


Läs hela artikeln här

Dagens Nyheter writes about Personalized Medicine

Dagens Nyheter recently published an article about personalized medicine featuring interviews with leading scientists in personalized medicine, including Professor Carsten Rose from CREATE Health.

Today, the same medicines have different effect for two people having the same disease. Many drugs are expensive and if they do not provide a particularly good effect, they only cause a lot of suffering for the patient and an unnecessary cost for society.

Personalized Medicine means giving the right drug at the right dose at the right time to the right patient. It may sound simple, but since many processes interact in these diseases, the big picture is really complicated. However, since for example genetic analysis has become both cheaper and faster, the potential for tailoring the medicine has increased.

By measuring all genes and their activity in cells, we can get a fingerprint of the disease and that will help the doctors tailoring the right treatment. 

- Instead of treating all patients in the same ways, we should only treat the patients having large chance for a good effect with a particular drug. In this case, the total price would be lower. In addition, it would be a great benefit for the patients, says Carsten Rose, professor in oncology at Lund University.

Photo credit: Superstock/Universal Group

SWELIFE satsar stort på Nya möjligheter

Ny nationell standard för sjukvårdsintegrerad biobankning ökar förutsättningarna för individanpassad hälso- och sjukvård, Personalised Medicine. Vi står inför ett paradigmskifte. Cancerbehandling kommer att grundas på orsakerna till sjukdomen och varje patients förutsättningar. Sofia Waldemarson, Projektledare SWElife, Forskare CREATE Health Cancer Center, berättar här om de senaste nyheterna på området. Läs hela artikeln här

CREATE Health celebrates 10 years!

Taken together, the CREATE Health team has included seven research groups from three faculties, focusing on translational cancer research. Several important scientific findings have been made during these ten years, leading to publications in high-impact journals as well as patents. A number of research findings have also been commercialised and contributed to the founding of spin-off companies.

The 10-year anniversary will be highlighted in a dedicated Newsletter spring 2016!

Debate article on personalized medicine published in Dagens Nyheter

According to US estimates, 90 per cent of all drugs are effective in less than half of all patients.  Therefore, both the US and EU are doing major investments in personalized medicine, while Sweden is currently falling behind. In the Swedish newspaper Dagens Nyheter, prominent researchers from five Swedish universities, including Professor Carl Borrebaeck from CREATE Health, emphasize the importance of similar investments in Sweden. The authors strongly urge financiers in Sweden to launch strategic research programs focusing on early and individualized drug therapies. The article was also highlighted in Dagens Medicin.

October is Breast cancer awareness month

Breast cancer mainly affects middle-aged and older women. The median age of onset is 64 years old. In total, more than 61,000 cancer diagnoses are made each year in Sweden. Of these, over 9000 are breast cancer diagnoses. This means that 20 women are diagnosed with breast cancer every day.

Earlier detection is vital to win the battle with all types of cancer. Lao Saal and his co-workers at CREATE Health show in their study that it is possible to detect metastases from breast cancer on average eleven months before they are detected with other methods, and in some cases 3 years before. They quantify circulating tumor DNA using a blood test to detect the metastatic disease. These results were highlighted on Swedish news channel TV4:

The study was funded by CREATE Health, CancerfondenVetenskapsrådet, Gunnar Nilssons Cancerstiftelse, Gyllenstiernska Krapperupsstiftelsen and fru Berta Kamprads Stiftelse and others.

Successful Cancer Crosslinks day the 14th of October

The Cancer Crosslinks conference took place on 14th of October at Medicon Village, Lund University, and was a great success. It was fully booked and participants could enjoy initiated lectures from various research facilities, both from commercial laboratories and from university. The theme was personalized medicine and immuno-oncology and how we can facilitate that research will reach clinical application more quickly. During the day there were many opportunities for networking and collaborative discussions.

US Rogosin Institute invests in MAD for Cancer

The US research institute, Rogosin Institute,  invests in the Lund-based research program and CREATE Health cooperator Make a Difference (MAD) for Cancer. The agreement gives the cancer research at Lund University new funds. Rogosin Institute has developed a general method to stop tumor growth, and the approach is to contain the tumor cells in particles of sugar and thereby produce proteins that stops the growth of tumor cells. Rogosin Institute is involved in this cooperation with  MAD for Cancer to be able to map the mechanisms underlying treatment.  For us it is very flattering and a very good rating for cancer research in Lund, says Carl Borrebaeck, Professor at Immunotechnology and Director at CREATE Health.

It is mainly the MAD for Cancer technology for protein analysis, led by Professor Peter James, that Rogosin Institute is interested in. - We have better equipment and more experience here in Lund than Rogosin themselves.

The first phase of the collaboration will be completed within a year and  MAD for Cancer receives funding of between two and three million Swedish kronor. - If ithis goes well, we will go on with the cooperation and the next phase gives us a much larger investment, says Carl Borrebaeck.

Professor Barry Smith, CEO of Rogosin Institute says; – MAD for Cancer is especially attractive for Rogosin becuause of it´s multifaceted approach to cancer system biology. This is an exciting and important opportunity for cooperation since we are going to be able to further develop our cancer project through this agreement. We feel priviliged to work with the team behind MAD for Cancer.

The program MAD for Cancer  was started by Carl Borrebaeck almost two years ago and brings together cancer research from four faculties at Lund University.

Read the Swedish news here.
Read more about Rogosin Institute here.

MAD for Cancer website is official

Make A Difference for Cancer (MAD for Cancer), is collaborating with CREATE Health, and has now gone live with their website. To read more about the research and Principal Investigators involved in this multifocal cancer program at Lund University, go here.

Carsten Peterson recieves the KVSU-prize

Professor Carsten Peterson was awarded The Royal Academy of Arts and Sciences of Uppsala (Kungliga Vetenskapssamhället i Uppsala) prize for his interdisciplinary work.  

The prize was parted at its annual ceremony in October 2014. He recieved the prize of 75.000 SEK for his “theteoretical physics based research that provides new knowledge about complex systems in molecular biology and medicine”. At the award ceremony Carsten held his laureate lecture "From stem cell to mature cell - a theoretical physicist´s perspective".

New movies about research within CREATE Health

Two new 3-minute movies about the work we do in CREATE Health has been produced in swedish by LTH and Lund University.

In "Fängslande forskning på LTH: Biomedicinsk teknik", Principal Investigator Thomas Laurell tells about lab-on-a-chip and the possibilities we get when we can diagnose cancer and even what treatment individual patients should get with this technique.

The other movie, "Fängslande forskning på LTH: Immunteknologi" revolves around Principal Investigator Sara Ek´s research and the technology developed to detect the aggressive cancer form called mantle cell lymphoma. A technology that is available for clinicians world-wide for better diagnostics.

Both movies can be found at Movies.




Carl Borrebaeck has been awarded the Royal Swedish Academy of Engineering Sciences, IVA, Gold Medal.

The justification is "his fundamental and pioneering research in applied immunology" and "his great entrepreneurship."

He will receive his medal on Friday, 28th of October at the Stockholm Concert Hall , from the Majesty King Carl XVI Gustaf during IVA’s 93rd Celebration Gathering.


Congratulations to Johan Malmström who will receive the very prestigious research grant of 1.5 million Euro from the European Research Council for the project where he uses advanced mass spectrometry to study the ability of Streptococcus pyogenes to cause infections.  


GPS - Global Proteome Survey

The CREATE Health PhD team has recently presented a new technique; Global Proteome Survey, in  apublication in Molecular and Cellular Proteomics. In addition, the technique was high-lighted in an editorial in Nature Metods. 

Download the article
Read the comment in Nature Methods

CREATE Health and Cancer
A short movie about CREATE Health and its main objectives. 
Watch the movie here.


Every Ten Minutes
Every third person in Sweden is diagnosed with cancer sometimes during their lifetime. This is 50 000 patients a year - one every ten minutes. This has named the movie that describes the translational research and clinical activities in southern Sweden.
 Watch the movie

Miljonanslag till bättre behandling av bröstcancer
En fjärdedel av alla de 7000 kvinnor som årligen drabbas av bröstcancer riskerar metastaser, alltså återfall. De senaste åren har forskare vid Lunds universitet utvecklat en teknik som på förhand kan ta reda på vilka patienter som tillhör denna riskgrupp. Inom de närmaste två åren kommer metoden att börja testas av sjukvården i Lund och Malmö.

Page Manager: